- Licofelone, a 5-lipoxygenase, Cyclooxygenase-1 and -2 inhibitor, is as effective as Celecoxib and shows improved tolerability in osteoarthritis of the kneePublication without faculty affiliation
- Neutral sphingomyelinase 2 inhibitors based on the pyrazolo[1,5-a] scaffold2023 | Faculty of Science
- Celecoxib, a Cyclooxygenase 2 Inhibitor as a Potential Chemopreventive to UV-Induced Skin2002 | First Faculty of Medicine
- Neutral sphingomyelinase 2 inhibitors based on the pyrazolo[1,5-a]pyrimidin-3-amine scaffold2023 | Faculty of Science
- Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque2008 | First Faculty of Medicine
- Inhibition of SGLT-2 as a new approach in the treatment of type 2 diabetes mellitus2013 | First Faculty of Medicine, Third Faculty of Medicine
- Diabetes mellitus and gynecological infections2015 | First Faculty of Medicine
- Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF2020 | First Faculty of Medicine
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Faculty of Pharmacy in Hradec Králové
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction2019 | First Faculty of Medicine
- U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells2014 | Faculty of Pharmacy in Hradec Králové
- Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin2022 | First Faculty of Medicine
- SGLT2 inhibitors and atherosclerosis in a background of effect of gliflozins and heart failure2021 | First Faculty of Medicine
- Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction2021 | First Faculty of Medicine
- Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology - summary of the document prepared by CKS2020 | First Faculty of Medicine
- New treatment options for chronic kidney disease - focused on SGLT2 inhibitors2021 | First Faculty of Medicine
- News in the treatment of heart failure - gliflozins in patients with a mildly reduced and preserved ejection fraction2023 | First Faculty of Medicine
- Dapagliflozin2013 | Faculty of Medicine in Hradec Králové
- Fournier's gangrene and gliflozins in therapy of diabetes mellitus2019 | Third Faculty of Medicine, Second Faculty of Medicine
- Expert consensus on the practical aspects of collaboration between cardiologists and diabetologists in the management of patients with chronic heart failure with reduced ejection fraction2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF2021 | First Faculty of Medicine
- Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index2021 | First Faculty of Medicine
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017 | Second Faculty of Medicine
- Experience with ruxolitinib in the treatment of myelofibrosis and polycythaemia vera at Czech haematological institutions2017 | Faculty of Medicine in Hradec Králové